Barrx Medical: Making A Case For Ablation
Barrx Medical set out seven years ago to compile enough clinical trial data to prove not only that ablation is a safe and effective way of treating Barrett's esophagus, but also that is cheaper than endoscopic surveillance. Its patience is beginning to pay off.
You may also be interested in...
NinePoint Medical Inc. is looking to shed some insights on the mysteries of the esophagus. The venture-backed start-up launched NvisionVLE, an imaging system that can produce real-time images of the esophagus, enabling gastroenterologists to see where they need to cut when performing biopsies of tests of worrisome esophageal tissue including Barrett’s esophagus.
Brief summaries of recent medtech market and industry developments. This month we cover Covidien’s continuing buying spree, and other medtech M&A.
Since its spin-out from Tyco, Covidien has spent close to $5 billion acquiring public and privately held device companies, with more than $1 billion of that being spent just over the past six months. The string of purchases bulked up every one of Covidien’s existing medical device businesses. In the recent acquisition of superDimension, Covidien paid $300 million plus earn-outs for the maker of the iLogic system, which uses electromagnetic navigation bronchoscopy technology. The purchase means Covidien’s sales force will begin calling more on interventional pulmonologists, potentially creating an exit route for other pulmonary start-ups.